Both KN3014 and MCC950 dose-dependently reduced the spontaneous auto-secretion of both IL-1β and TNF-α, suggesting that KN3014 may be a candidate therapeutic agent for the treatment of patients with CAPS (Fig. 5a–d). Here, TNF is linked to cryopyrin-associated periodic syndrome.